[HTML][HTML] 晚期非小细胞肺癌HER2 基因突变靶向治疗进展
孔令平， 钟殿胜 - Chinese Journal of Lung Cancer, 2020 - ncbi.nlm.nih.gov
肺癌是最常见的恶性肿瘤， 非小细胞肺癌（ non-small cell lung cancer, NSCLC）
发生率约占所有肺癌的85%。 人表皮生长因子受体2（ human epidermal growth factor receptor …
发生率约占所有肺癌的85%。 人表皮生长因子受体2（ human epidermal growth factor receptor …
Research Progress of Targeted Therapy for HER2 Gene in Advanced Non-small Cell Lung Cancer
K Lingping, D ZHONG - Zhongguo Fei Ai Za Zhi, 2020 - search.proquest.com
肺癌是最常见的恶性肿瘤, 非小细胞肺癌 (non-small cell lung cancer, NSCLC)
发生率约占所有肺癌的 85%. 人表皮生长因子受体 2 (human epidermal growth factor receptor …
发生率约占所有肺癌的 85%. 人表皮生长因子受体 2 (human epidermal growth factor receptor …
Research Progress of Targeted Therapy for HER2 Gene in Advanced Non-small Cell Lung Cancer
L Kong, D Zhong - Zhongguo fei ai za zhi= Chinese Journal of Lung …, 2020 - europepmc.org
肺癌是最常见的恶性肿瘤, 非小细胞肺癌 (non-small cell lung cancer, NSCLC)
发生率约占所有肺癌的 85%. 人表皮生长因子受体 2 (human epidermal growth factor receptor …
发生率约占所有肺癌的 85%. 人表皮生长因子受体 2 (human epidermal growth factor receptor …
[HTML][HTML] HER2 基因状态与晚期肺腺癌患者一线培美曲塞联合铂类化疗疗效的关系
李盼华， 李班班， 史云舒， 张凤鸣， 申淑景… - Chinese Journal of …, 2019 - ncbi.nlm.nih.gov
背景与目的人类表皮生长因子受体2 (human epidermal growth factor receptor 2, HER2)
突变是非小细胞肺癌(non-small cell lung cancer, NSCLC) 的分子标记物之一 …
突变是非小细胞肺癌(non-small cell lung cancer, NSCLC) 的分子标记物之一 …
[HTML][HTML] HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches
AC Garrido-Castro, E Felip - Translational lung cancer research, 2013 - ncbi.nlm.nih.gov
Oncogenic driver mutations identified in non-small cell lung cancer (NSCLC) have triggered
the development of drugs capable of interfering in intracellular signaling pathways involved …
the development of drugs capable of interfering in intracellular signaling pathways involved …
人表皮生长因子受体2 突变型非小细胞肺癌的治疗现状与展望.
徐菲， 王燕 - Chinese Journal of Oncology, 2020 - search.ebscohost.com
自人表皮生长因子受体2 (HER⁃ 2) 变异被发现并确定为恶性肿瘤增殖驱动基因之后,
靶向HER⁃ 2 治疗在乳腺癌, 胃癌领域中均取得了良好疗效. 同属表皮生长因子受体(EGFR) …
靶向HER⁃ 2 治疗在乳腺癌, 胃癌领域中均取得了良好疗效. 同属表皮生长因子受体(EGFR) …
[HTML][HTML] HER2 阳性非小细胞肺癌诊断及治疗进展
REN Chenyi, CAO He, Z Jing… - Chinese Journal of …, 2023 - ncbi.nlm.nih.gov
肺癌是全球最常见的恶性肿瘤， 也是癌症死亡的主要原因。 人表皮生长因子受体2（ human
epidermal growth factor receptor 2, HER2） 阳性非小细胞肺癌（ non-small cell lung cancer …
epidermal growth factor receptor 2, HER2） 阳性非小细胞肺癌（ non-small cell lung cancer …
Role of HER2 in NSCLC
K Zhang, W Hong - Zhongguo Fei Ai Za Zhi, 2015 - search.proquest.com
过去几年中, 随着分子靶向药物的引入, 非小细胞肺癌 (non-small cell lung cancer, NSCLC)
的药物治疗策略发生了巨大变化, 向基于组织学和分子水平的治疗手段转变. 表皮生长因子受体 …
的药物治疗策略发生了巨大变化, 向基于组织学和分子水平的治疗手段转变. 表皮生长因子受体 …
Progress in treatment of non-small cell lung cancer harboring HER2 aberrations
J Ni, L Zhang - OncoTargets and therapy, 2021 - Taylor & Francis
Epidermal growth factor receptor 2 (HER2/ErbB2/neu), a member of ErbB receptor tyrosine
kinase family, forms homo-or heterodimers with ErbB1 (HER1/EGFR), ErbB3 (HER3), or …
kinase family, forms homo-or heterodimers with ErbB1 (HER1/EGFR), ErbB3 (HER3), or …
[HTML][HTML] Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains
C Li, Y Sun, R Fang, X Han, X Luo, R Wang… - Journal of Thoracic …, 2012 - Elsevier
Introduction A fraction of lung adenocarcinomas harbor activating mutations in the HER2
kinase domain. HER2-targeted therapies have shown minimal benefit in molecularly …
kinase domain. HER2-targeted therapies have shown minimal benefit in molecularly …